2026, February 12

Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with Grade 2 IDH-mutant glioma

2026, April 21

Advancing Targeted Care for Adults with Genetically Defined Acute Myeloid Leukemia (AML)